Innovative
Therapeutics for
Better Health

Because Life
Shouldn't Have to
Wait for Migraines

Our Lead Product Candidate

STS101

Dihydroergotamine (DHE) Nasal Powder

Learn More

Clinical Trials

SUMMIT™ Trial

Completed

Learn More

Clinical Trials

ASCEND™ Trial

Completed

Learn More

Press Releases

Jun 15, 2023

Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting

Read More

May 18, 2023

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine

Read More